Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Poltreg S.A. (PTG.WA)
PLN19.30
-0.10 (-0.52%)
PL WSE Healthcare Biotechnology
Address
Waly Piastowskie 1 lok. 1508 80-855
Gdansk, PL
Gdansk, PL
CEO
Piotr Trzonkowsk
Website
poltreg.tech
IPO
2021-11-23
ISIN PLPLTRG00038
Description
Poltreg S.A. is a biotechnology enterprise based in Gdansk, Poland, specializing in the creation of therapeutic solutions for autoimmune conditions. The company's research and development efforts are centered on harnessing T-regulatory cells to develop treatments, specifically targeting type 1 diabetes in children and multiple sclerosis.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN19.30
-0.10 (-0.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8.4K
Beta
0.91
Float Shares
2.08M
Free Float %
44.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -6.44% | +11.18% | -26.74% | -29.48% | -25.88% | -47.06% | -62.94% | -69.51% | -69.51% | -69.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
19.30
DCF (Unlevered)
3.11
-83.9%
DCF (Levered)
2.18
-88.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.04
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-39.2% Q1'26: -23.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-107.1% Q1'26: -104.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.26× Q1'26: -0.25× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
999.0K
est: 1.40M (-28.5%)
|
1.40M
est: 900.0K (+55.4%)
|
350.0K
est: 800.0K (-56.3%)
|
—
est: 133.3K (-100.0%)
|
12.00M
12.00M – 12.00M
+8,900.0% YoY
|
119.00M
119.00M – 119.00M
+891.7% YoY
|
133.50M
133.50M – 133.50M
+12.2% YoY
|
| EBITDA |
-860.0K
est: -1.17M (+26.2%)
|
-11.66M
est: -750.8K (-1,453.0%)
|
-13.87M
est: -457.7K (-2,929.0%)
|
-29.86M
est: -76.3K (-39,039.3%)
|
-6.87M
-6.87M – -6.87M
-8,900.1% YoY
|
-68.09M
-68.09M – -68.09M
-891.7% YoY
|
-76.38M
-76.38M – -76.38M
-12.2% YoY
|
| EBIT |
-1.68M
est: -1.40M (-20.5%)
|
-12.72M
est: -900.0K (-1,313.0%)
|
-17.87M
est: -480.0K (-3,623.1%)
|
-35.52M
est: -80.0K (-44,296.8%)
|
-7.20M
-7.20M – -7.20M
-8,900.1% YoY
|
-71.40M
-71.40M – -71.40M
-891.7% YoY
|
-80.10M
-80.10M – -80.10M
-12.2% YoY
|
| Net Income |
-1.97M
est: -8.78M (+77.6%)
|
-13.55M
est: -15.64M (+13.4%)
|
-18.71M
est: 2.81M (-765.8%)
|
-26.00M
est: -27.51M (+5.5%)
|
-13.01M
-13.01M – -13.01M
+52.7% YoY
|
50.97M
50.97M – 50.97M
+491.8% YoY
|
45.42M
45.42M – 45.42M
-10.9% YoY
|
| SGA |
3.50M
est: 6.52M (-46.2%)
|
4.38M
est: 4.20M (+4.2%)
|
4.44M
est: 3.61M (+23.0%)
|
28.52M
est: 601.9K (+4,638.4%)
|
54.18M
54.18M – 54.18M
+8,900.0% YoY
|
537.24M
537.24M – 537.24M
+891.7% YoY
|
602.70M
602.70M – 602.70M
+12.2% YoY
|
| EPS |
-0.42
est: -1.88 (+77.7%)
|
-2.91
est: -3.35 (+13.3%)
|
-4.01
est: 0.60 (-765.5%)
|
-5.58
est: -5.90 (+5.4%)
|
-2.79
-2.79 – -2.79
+52.7% YoY
|
10.93
10.93 – 10.93
+491.8% YoY
|
9.74
9.74 – 9.74
-10.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-50.61M
OE per share TTM
-10.85
Owner's Yield
-57.43%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3,609.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
4.66M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Piotr Trzonkowsk | President of the Management Board | 640.0K | male |
| Paulina Kocenko-Merks | Chief Financial Officer & Member of Management Board | 375.0K | female |
| Mariusz Jablonski | Member of the Management Board | 344.0K | male |
| Kamilla Agnieszka Bok | Director of Operations | 224.0K | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PTG.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
